Bristol-Myers Squibb Co (NYSE:BMY) Given Consensus Recommendation of “Buy” by Brokerages

Bristol-Myers Squibb Co (NYSE:BMY) has been given a consensus recommendation of “Buy” by the nineteen research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $53.80.

BMY has been the topic of a number of research reports. JPMorgan Chase & Co. set a $62.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. Mizuho boosted their price objective on Bristol-Myers Squibb from $3.14 to $3.99 in a research note on Monday. ValuEngine raised Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 19th. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, November 18th. Finally, Morgan Stanley initiated coverage on Bristol-Myers Squibb in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 price objective on the stock.

In other news, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares in the company, valued at $1,807,827.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the company. Garrett Wealth Advisory Group LLC purchased a new position in shares of Bristol-Myers Squibb during the third quarter valued at $26,000. Lenox Wealth Advisors LLC grew its stake in Bristol-Myers Squibb by 555.7% in the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. grew its stake in Bristol-Myers Squibb by 101.2% in the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 327 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in Bristol-Myers Squibb by 52.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 230 shares in the last quarter. Finally, 1 North Wealth Services LLC purchased a new position in Bristol-Myers Squibb in the third quarter valued at about $41,000. Institutional investors and hedge funds own 83.13% of the company’s stock.

Shares of BMY traded up $1.22 during midday trading on Monday, reaching $61.18. The stock had a trading volume of 7,092,741 shares, compared to its average volume of 27,050,048. Bristol-Myers Squibb has a 52 week low of $42.48 and a 52 week high of $60.86. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The firm’s 50 day moving average price is $56.65 and its 200-day moving average price is $49.68. The company has a market capitalization of $97.68 billion, a P/E ratio of 15.37, a P/E/G ratio of 1.39 and a beta of 0.70.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The company had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. During the same quarter in the previous year, the business earned $1.09 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, equities analysts forecast that Bristol-Myers Squibb will post 4.38 earnings per share for the current year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: What does an outperform rating mean?